Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus

Title:Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus

Volume: 13 Issue: 7

Author(s): Ghulam M. Ashraf, Nigel H. Greig, Taqi A. Khan, Iftekhar Hassan, Shams Tabrez, Shazi Shakil, Ishfaq A. Sheikh, Syed K. Zaidi, Mohammad Akram, Nasimudeen R. Jabir, Chelaprom K. Firoz, Aabgeena Naeem, Ibrahim M. Alhazza, Ghazi A. Damanhouri and Mohammad A. Kamal

Affiliation:

Keywords: Alzheimer's disease, amylin, amyloid-β, amyloid precursor protein, islet amyloid polypeptide, neurofibrillary tangles, Parkinson's disease, protein folding, proteostasis, tau, tauopathy, type 2 diabetes mellitus, α-synuclein.

Abstract: In general, proteins can only execute their various biological functions when they are appropriately folded. Their amino acid sequence encodes the relevant information required for correct three-dimensional folding, with or without the assistance of chaperones. The challenge associated with understanding protein folding is currently one of the most important aspects of the biological sciences. Misfolded protein intermediates form large polymers of unwanted aggregates and are involved in the pathogenesis of many human diseases, including Alzheimer’s disease (AD) and Type 2 diabetes mellitus (T2DM). AD is one of the most prevalent neurological disorders and has worldwide impact; whereas T2DM is considered a metabolic disease that detrementally influences numerous organs, afflicts some 8% of the adult population, and shares many risk factors with AD. Research data indicates that there is a widespread conformational change in the proteins involved in AD and T2DM that form β-sheet like motifs. Although conformation of these β-sheets is common to many functional proteins, the transition from α-helix to β-sheet is a typical characteristic of amyloid deposits. Any abnormality in this transition results in protein aggregation and generation of insoluble fibrils. The abnormal and toxic proteins can interact with other native proteins and consequently catalyze their transition into the toxic state. Both AD and T2DM are prevalent in the aged population. AD is characterized by the accumulation of amyloid-β (Aβ) in brain, while T2DM is characterized by the deposition of islet amyloid polypeptide (IAPP, also known as amylin) within beta-cells of the pancreas. T2DM increases pathological angiogenesis and immature vascularisation. This also leads to chronic cerebral hypoperfusion, which results in dysfunction and degeneration of neuroglial cells. With an abundance of common mechanisms underpinning both disorders, a significant question that can be posed is whether T2DM leads to AD in aged individuals and the associations between other protein misfolding diseases.

Cite this article as:

Ashraf M. Ghulam, Greig H. Nigel, Khan A. Taqi, Hassan Iftekhar, Tabrez Shams, Shakil Shazi, Sheikh A. Ishfaq, Zaidi K. Syed, Akram Mohammad, Jabir R. Nasimudeen, Firoz K. Chelaprom, Naeem Aabgeena, Alhazza M. Ibrahim, Damanhouri A. Ghazi and Kamal A. Mohammad, Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus, CNS & Neurological Disorders - Drug Targets 2014; 13 (7) . https://dx.doi.org/10.2174/1871527313666140917095514